当前位置: 首页 >> 检索结果
共有 17708 条符合本次的查询结果, 用时 2.4495982 秒

281. G-Protein-Coupled Estrogen Receptor 1 and Pregnancy Confer Protection Against Hypertension in Older Females.

作者: Ravneet Singh.;Supaporn Kulthinee.;Victoria L Nasci.;Elvis A Akwo.;Chibundu Juliet Umunna.;Rawan N Almutlaq.;Oleh M Pochynyuk.;Cassianne Robinson-Cohen.;Eman Y Gohar.
来源: Circulation. 2025年151卷15期1126-1129页

282. Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality.

作者: Emmanuel Stamatakis.;Raaj K Biswas.;Nicholas A Koemel.;Angelo Sabag.;Richard Pulsford.;Andrew J Atkin.;Afroditi Stathi.;Sonia Cheng.;Cecilie Thøgersen-Ntoumani.;Joanna M Blodgett.;Adrian Bauman.;Carlos Celis-Morales.;Mark Hamer.;Jason M R Gill.;Matthew N Ahmadi.
来源: Circulation. 2025年151卷15期1063-1075页
Few middle-aged and older adults engage in regular leisure-time exercise. Incidental physical activity (IPA) encompasses activities of daily living outside the leisure-time domain. No dose-response study is available to guide IPA-focused interventions and guidelines. We examined the associations of device-assessed IPA intensities (vigorous [VIPA], moderate [MIPA], light [LIPA]) with major adverse cardiovascular events (MACE) and mortality, and we estimated the "health equivalence" of LIPA and MIPA against 1 minute of VIPA.

283. Patient-Reported Outcomes as End Points in Heart Failure Trials.

作者: Javed Butler.;Muhammad Shariq Usman.;Charu Gandotra.;Ali Salman.;Andrew Farb.;Aliza M Thompson.;Norman Stockbridge.;Cordula Zeller.;Folke Folkvaljon.
来源: Circulation. 2025年151卷15期1111-1125页
Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized. Regulatory agencies consider PROs part of their evaluation of drugs and devices, and professional society guidelines may recommend interventions that improve PROs. However, for several reasons, the effect of interventions on PROs reported in heart failure trials currently is difficult to interpret. There is no consensus on the timing and frequency of PRO assessments. Moreover, it has been difficult to establish a minimal clinically important difference, that is, the minimal change in a PRO score that is meaningful to a patient. In addition, traditional methods of analyzing and reporting PROs such as comparison of mean differences across groups or responder analysis are prone to statistical artifacts and misinterpretation. This article presents an in-depth discussion of these issues, with the Kansas City Cardiomyopathy Questionnaire used as an example, to facilitate the use of PROs in heart failure research, regulatory, and clinical settings.

284. Letter by Lu et al Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices".

作者: Xiaofeng Lu.;Shaowen Liu.;Songwen Chen.
来源: Circulation. 2025年151卷15期e923-e924页

285. Optimal Oversizing With the New-Generation Evolut (PRO/PRO+/FX) Self-Expanding Valves: A Multicenter Study.

作者: Silvia Mas-Peiro.;Alberto Alperi.;Ander Regueiro.;Ignacio Cruz-Gonzalez.;Domenico Angellotti.;Francisco Campelo-Parada.;Marina Urena.;Pablo Avanzas.;Pablo Vidal-Cales.;Gilles Jose Barreira de Sousa.;Giovanni Esposito.;Mehdi Tamir.;Gaspard Suc.;Anthony Poulin.;Siamak Mohammadi.;Marisa Avvedimento.;Josep Rodés-Cabau.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014916页
Paravalvular leaks (PVLs) after transcatheter aortic valve replacement have a significant prognostic impact, and valve oversizing, particularly with self-expanding valves, may prevent postprocedural PVL occurrence. Recent iterations of the Evolut valve system are intended to reduce PVL, but the effects of oversizing with such valves on PVL are largely unknown. We aimed to assess, in a real-world contemporary setting, the impact of Evolut valve oversizing on PVL after transcatheter aortic valve replacement.

286. Two Years Transplant-Free Survival After LVAD Explantation in a Titin Truncating Variant Carrier With Peripartum Cardiomyopathy and Cardiogenic Shock.

作者: Rita Godinho.;Anna Nowacka.;Zahurul Bhuiyan.;Zied Ltaief.;Lucas Liaudet.;Matthias Kirsch.;Patrick Yerly.
来源: Circ Heart Fail. 2025年e012079页

287. Gaps and Knowledge in the Contemporary Management of Acute Right Ventricular Failure.

作者: Paolo Manca.;Vincenzo Nuzzi.;Massimiliano Mulè.;Sergio Sciacca.;Matteo Castrichini.;Uwe Schulz.;Naveen Pereira.;Holger Thiele.;Jacob Jentzer.;Manlio Cipriani.
来源: Circ Heart Fail. 2025年e012030页
Acute right ventricular failure (ARVF) is commonly seen in the intensive care unit and constitutes a significant clinical challenge, with associated high in-hospital mortality. Recently, the treatment of ARVF has significantly changed, with the progressive implementation of mechanical circulatory support devices that now represent important tools for clinicians in treating this condition. However, despite recent advancements, the optimal approach for ARVF remains elusive, and precise treatment algorithms and comprehensive management protocols are still lacking. In the present review, we explore the pathophysiology of ARVF, highlighting the different mechanisms that may lead to this clinical entity and emphasizing the left and right heart's complex interplay. We analyze the different therapeutic options that are now available for short- and long-term management of ARVF, with a particular focus on the advantages and disadvantages of the mechanical circulatory support devices actually used. Furthermore, we propose future directions in the field and a possible flowchart for the treatment of this condition.

288. Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure.

作者: Michael R Zile.;William T Abraham.;Lynne W Stevenson.;Maria Rosa Costanzo.;Christiane E Angermann.;Mandeep R Mehra.;Akshay S Desai.;Anique Ducharme.;Nessa Johnson.;John Henderson.;JoAnn Lindenfeld.
来源: Circ Heart Fail. 2025年18卷6期e012754页
Hemodynamically guided management of patients with chronic heart failure (HF), using a remote, ambulatory pulmonary artery (PA) pressure monitor, has been shown to reduce mortality and morbidity. These improved outcomes were associated with a reduction in PA pressure. However, several pivotal questions remain unanswered: do systolic, diastolic, or mean PA pressures each predict all-cause mortality? Do PA pressures predict mortality across the ejection fraction (EF) spectrum? Do increases or decreases in PA pressure over time predict increases or decreases in mortality?

289. Chronic Total Occlusion Percutaneous Coronary Intervention: Present and Future.

作者: Emmanouil S Brilakis.;Yader Sandoval.;Lorenzo Azzalini.;Gregor Leibundgut.;Roberto Garbo.;Allison B Hall.;Rhian E Davies.;Kambis Mashayekhi.;Masahisa Yamane.;Alexandre Avran.;Jaikirshan J Khatri.;Khaldoon Alaswad.;Farouc A Jaffer.;Stephane Rinfret.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014801页
Chronic total occlusion percutaneous coronary intervention has evolved into a subspecialty of interventional cardiology. Using a variety of antegrade and retrograde techniques, experienced operators currently achieve success rates of 85% to 90%, with an incidence of major periprocedural complications of ≈2% to 3%. Several developments in equipment (new microcatheters and guidewires, novel reentry devices), imaging (computed tomography angiography guidance, intravascular imaging for reentry), techniques (intraocclusion contrast injection, advanced subintimal tracking and reentry), and artificial intelligence (automated computed tomography image analysis and prediction of the likelihood of crossing success with various techniques) could further improve outcomes. Global collaboration and rapid dissemination of new developments accelerate the pace of progress. While innovation is exciting and necessary, adhering to the basic principles of chronic total occlusion percutaneous coronary intervention (such as continual assessment of risks and benefits, meticulous angiographic review, and use of dual injection) remains critical for achieving optimal patient outcomes.

290. Multidimensional Sleep Health: Definitions and Implications for Cardiometabolic Health: A Scientific Statement From the American Heart Association.

作者: Marie-Pierre St-Onge.;Brooke Aggarwal.;Julio Fernandez-Mendoza.;Dayna Johnson.;Christopher E Kline.;Kristen L Knutson.;Nancy Redeker.;Michael A Grandner.; .
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e000139页
Poor sleep health is associated with cardiometabolic disease and related risk factors, including heart disease, stroke, elevated blood pressure and lipid levels, inflammation, glucose intolerance, obesity, physical inactivity, poor diet, unhealthy substance use, poor mental health, and increased all-cause and cardiovascular mortality, and is associated with social determinants of cardiovascular health and health disparities. Therefore, sleep duration has been recognized by the American Heart Association as one of Life's Essential 8. Although chronic sleep duration is the sole metric used in Life's Essential 8, sleep health represents a multidimensional construct. This scientific statement outlines the concept of multidimensional sleep health (sleep duration, continuity, timing, regularity, sleep-related daytime functioning, architecture, and absence of sleep disorders) as it applies to cardiometabolic health. Considerations of how these dimensions are related to cardiometabolic health and patterned by sociodemographic status are explained, and knowledge gaps are highlighted. Additional data are needed to understand better how these various dimensions of sleep should be assessed and how interventions targeting sleep health in clinical and community settings can be leveraged to improve health.

291. Effect of TAVI on Epicardial Functional Indices and Their Relationship to Coronary Microvascular Function.

作者: Emanuele Gallinoro.;Roberto Scarsini.;Marco B Ancona.;Pasquale Paolisso.;Leonardo Portolan.;Paolo Springhetti.;Francesco Della Mora.;Andrea Mainardi.;Marta Belmonte.;Francesco Moroni.;Luca A Ferri.;Barbara Bellini.;Filippo Russo.;Ciro Vella.;Michele Mattia Viscusi.;Thabo Mahendiran.;Gabriele Pesarini.;Giovanni Benfari.;Matteo Montorfano.;Flavio Ribichini.;Marc Vanderheyden.;Emanuele Barbato.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014940页
The anatomic and physiological changes associated with severe aortic stenosis may influence the functional evaluation of coronary stenoses. In this study, we aimed to assess changes in functional resting and hyperemic indices before and immediately after transcatheter aortic valve implantation (TAVI) and their relationship with microvascular resistance.

292. Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy.

作者: Yan Zou.;Jing Lu.;Zhipeng Lian.;Jianguo Jia.;Juan Shen.;Qianhe Li.;Jennifer Ming Jen Wong.;Kejia Jin.;Wendi Yan.;Xinyue Ren.;Yang Zhang.;Chenxing Huang.;Huanjie Yang.;Feng Huang.;Jun Li.;Junyu Zhai.;Yamei Xu.;Xialian Xu.;Hang Yu.;Yi Jin.;Hui Gong.;Jinzhong Lin.;Junbo Ge.;Yuxiang Dai.
来源: Circulation. 2025年151卷25期1780-1796页
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear.

293. Deletion of Exon 51 in a Humanized Duchenne Muscular Dystrophy Mouse Model Abolishes Ventricular Arrhythmia Predisposition.

作者: Robin M Perelli.;Madeleine J Sitton.;Joel D Bohning.;Adrian Pickar-Oliver.;K Tyler McCullough.;Mary E Moya-Mendez.;Scott Zheng.;Heather Daniels.;Garth Devlin.;Aravind Asokan.;Charles A Gersbach.;Andrew P Landstrom.
来源: Circ Genom Precis Med. 2025年18卷3期e004867页

294. Clonal Hematopoiesis of Indeterminate Potential in Chronic Coronary Disease: A Report From the ISCHEMIA Trials Biorepository.

作者: Matthew A Muller.;Richard Liu.;Farheen Shah.;Jiyuan Hu.;Claes Held.;Iftikhar J Kullo.;Bruce M McManus.;Lars Wallentin.;L Kristin Newby.;Mandeep S Sidhu.;Sripal Bangalore.;Harmony R Reynolds.;Judith S Hochman.;David J Maron.;Kelly V Ruggles.;Jeffrey S Berger.;Jonathan D Newman.
来源: Circ Genom Precis Med. 2025年18卷3期e004921页

295. Sedentary Behavior and Light-Intensity Physical Activity During Pregnancy and Cardiovascular Health: A Science Advisory From the American Heart Association.

作者: Kara M Whitaker.;Bethany Barone Gibbs.;Marie-France Hivert.;Nour Makarem.;Elizabeth Moxley.;Jason Vaught.;Kelly R Evenson.; .
来源: Circulation. 2025年151卷19期e990-e999页
The Physical Activity Guidelines for Americans supports sitting less and moving more. Growing evidence suggests that a waking behavior profile with less sedentary behavior and more light-intensity physical activity is associated with more favorable cardiovascular health. Remarkably, little is known about how these behaviors relate to cardiovascular health during pregnancy. The purpose of this American Heart Association science advisory is to describe the existing evidence on device-measured sedentary behavior and light-intensity physical activity in relation to cardiovascular health during pregnancy and to make specific calls to action for future research to improve health outcomes and to promote health equity. Outcomes included adverse pregnancy outcomes associated with increased risk of cardiovascular disease and the American Heart Association's Life's Essential 8 health factor components (blood pressure, lipids, glucose, and gestational weight gain). Findings from observational studies are mixed, with preliminary evidence demonstrating an association between high sedentary behavior and increased risk of hypertensive disorders of pregnancy, shorter gestational age at delivery, low or high birth weight, and elevated maternal blood pressure, lipids, glucose, and gestational weight gain. Findings for light-intensity physical activity are limited by fewer studies and are less compelling. Experimental evidence evaluating the impact of decreasing sedentary behavior or increasing light-intensity physical activity on pregnancy cardiovascular health is weak. Future observational studies with rigorous longitudinal designs and larger, diverse samples are needed to characterize associations and to inform the design of adequately powered randomized controlled trials testing the impact of decreasing sedentary behavior and increasing light-intensity physical activity on cardiovascular health during pregnancy.

296. Multimodality Imaging of Arrhythmic Risk in Mitral Valve Prolapse.

作者: Luca Cristin.;Lionel Tastet.;Dipan J Shah.;Marc A Miller.;Francesca N Delling.
来源: Circ Cardiovasc Imaging. 2025年18卷5期e017313页
Mitral valve prolapse (MVP) affects 2% to 3% of the general population and is typically benign. However, a subset of patients may develop arrhythmic complications, including sudden cardiac arrest and sudden cardiac death. This review explores the critical role of multimodality imaging in risk stratification for arrhythmic MVP, emphasizing high-risk features such as bileaflet involvement, mitral annular disjunction, the double-peak strain pattern, mechanical dispersion, and myocardial fibrosis. Echocardiography remains the first-line imaging tool for MVP diagnosis, enabling detailed assessment of leaflet morphology, mitral annular disjunction, and mitral regurgitation quantification. Speckle tracking provides insights into abnormal valvular-myocardial mechanics as a potential arrhythmogenic mechanism in MVP. Cardiac magnetic resonance (CMR) offers detailed myocardial tissue characterization through assessment of replacement and interstitial fibrosis using late gadolinium enhancement and T1 mapping/extracellular volume fraction, respectively. Hybrid positron emission tomography/CMR highlights the role of inflammation, which may coexist with fibrosis, in explaining the presence of malignant arrhythmias even with relatively limited fibrosis. The assessment of diffuse fibrosis and inflammation by CMR and positron emission tomography/CMR is particularly valuable in patients without classic imaging risk factors such as mitral annular disjunction, severe mitral regurgitation, or replacement fibrosis. We propose an algorithm integrating clinical, rhythmic, echocardiographic, CMR, and positron emission tomography/CMR parameters for arrhythmic risk stratification and management. Although multimodality imaging is essential for comprehensive risk assessment, most available parameters have not yet been validated in prospective studies nor linked directly to mortality. Consequently, these imaging findings should be interpreted alongside the presence of complex ventricular ectopy, which remains the most robust predictor of mortality in arrhythmic MVP.

297. Computational Modeling of Effects of PKP2 Gene Therapy on Ventricular Conduction Properties in Arrhythmogenic Cardiomyopathy.

作者: Alessio Ostini.;André G Kléber.;Yoram Rudy.;Jeffrey E Saffitz.;Jan P Kucera.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013658页
Patients with arrhythmogenic cardiomyopathy due to pathogenic variants in PKP2, the gene for the desmosomal protein plakophilin-2, are being enrolled in gene therapy trials designed to replace the defective allele via adeno-associated viral transduction of cardiac myocytes. Evidence from experimental systems and patients indicates that ventricular myocytes in PKP2 arrhythmogenic cardiomyopathy have greatly reduced electrical coupling at gap junctions and reduced Na+ current density. In previous adeno-associated viral gene therapy trials, <50% of ventricular myocytes have generally been transduced.

298. Response to Mavacamten in Patients With High Baseline Left Ventricular Filling Pressures in the EXPLORER-HCM Trial.

作者: Sharon Cresci.;Richard G Bach.;Anjali T Owens.;Neal K Lakdawala.;Sara Saberi.;Sheila M Hegde.;Ester Kim Nilles.;Daniel M Wojdyla.;Amy J Sehnert.;Andrew Wang.
来源: Circ Cardiovasc Imaging. 2025年18卷6期e017824页

299. Correction to: Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension.

作者: Jason Hong.;Lejla Medzikovic.;Wasila Sun.;Brenda Wong.;Grégoire Ruffenach.;Christopher J Rhodes.;Adam Brownstein.;Lloyd L Liang.;Laila Aryan.;Min Li.;Arjun Vadgama.;Zeyneb Kurt.;Tae-Hwi Schwantes-An.;Elizabeth A Mickler.;Stefan Gräf.;Mélanie Eyries.;Katie A Lutz.;Michael W Pauciulo.;Richard C Trembath.;Frédéric Perros.;David Montani.;Nicholas W Morrell.;Florent Soubrier.;Martin R Wilkins.;William C Nichols.;Micheala A Aldred.;Ankit A Desai.;David-Alexandre Trégouët.;Soban Umar.;Rajan Saggar.;Richard Channick.;Rubin M Tuder.;Mark W Geraci.;Robert S Stearman.;Xia Yang.;Mansoureh Eghbali.
来源: Circulation. 2025年151卷14期e921页

300. Predicting Cardiovascular Risk With Use of Various Tobacco Products.

作者: Neal L Benowitz.
来源: Circulation. 2025年151卷14期1006-1008页
共有 17708 条符合本次的查询结果, 用时 2.4495982 秒